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virulence studies, as it reduces the number of
PCRs from four to one.
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ABSTRACT
Mycoplasma pneumoniae antibodies were studied
in 504 blood donors and 102 patients with
infections not caused by M. pneumoniae with the
use of enzyme immunoassay kits from Thermo-
Labsystems (L), Savyon (S), Bio-Rad (B) and
Novitec (N). Detection frequencies of M. pneumo-
niae IgM in blood donors were 14.9% (L), 16.0%
(S), 2.8% (B) and 3.8% (N), and in patients were
40.2% (L), 42.2% (S), 9.8% (B) and 16.7% (N).
Detection frequencies of M. pneumoniae IgA were
68.5% (L) and 22.8% (S), and in 65 respiratory
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disease patients were 100% (L) and 53.8% (S).
Thus, use of some kits may lead to overdiagnosis
of M. pneumoniae infections.
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Mycoplasma pneumoniae is an important cause of
community-acquired pneumonia and respiratory
tract infections. Since the symptoms are non-
specific and may be caused by a variety of other
pathogens, serodiagnosis by complement fixation
and enzyme immunoassay (EIA) remains the
main diagnostic method for screening [1,2]. Pos-
itive serological results for M. pneumoniae may be
followed by antibiotic treatment if clinical symp-
toms are present. Consequently, false-positive
EIA results may lead to unnecessary use of
antimicrobial agents. The use of various immu-
noglobulin classes (IgG, IgM and IgA) to support
the serodiagnosis of M. pneumoniae-associated
infections from a single serum sample is currently
being investigated. The presence of IgM is asso-
ciated with current infection with M. pneumoniae,
especially in children [3,4], but IgM is difficult to
detect in adults [1].
False-positive results have been described pre-
viously with commercially available tests [5,6].
M. pneumoniae IgM may persist for up to a year
after infection [7], while IgA might be useful to
detect current infection, possibly in combination
with IgM [8–12]. Detection of IgG antibodies
might be valuable for demonstrating past or
recent infection if paired sera are used, i.e., acute
and convalescent specimens. The aim of the
present study was to investigate the use of
four different commercially available EIAs for
M. pneumoniae under routine conditions.
The following groups of sera were included in
the study: group A, 504 sera from blood donors in
the county of Vest-Agder in southern Norway;
group B, 20 sera positive for heterophile antibod-
ies, positive for Epstein–Barr virus capsid antigen
IgM and IgG, but negative for Epstein–Barr virus
nuclear antigen-1 IgG; group C, 15 sera positive
by adenovirus complement fixation test; group D,
17 sera positive by influenza A virus complement
fixation test; group E, five sera positive by
influenza B virus complement fixation test; group
F, 17 sera positive for Bordetella pertussis IgG, IgA
and IgM; group G, 17 sera from patients positive
for Ureaplasma urealyticum (16 patients) or Myco-
plasma hominis (one patient); and group H, 11 sera
from patients with positive blood cultures for
Streptococcus pneumoniae. Patients in groups C, D,
E, F and H had complications (e.g., persistent
cough, pneumonia) that were typical of the
underlying respiratory disease.
The sera were tested with the following EIA
kits: (1) Mycoplasma pneumoniae IgM, IgG and IgA
EIA (L; ThermoLabsystems, Helsinki, Finland), in
which surface-exposed P1 adhesin (168-kDa)
enriched antigen is used; (2) SeroMP (S; Savyon
Diagnostics, Ashdod, Israel), which is a semi-
quantitative EIA with a preparation of M. pneu-
moniae P1 membrane protein to detect IgM, IgG
and IgA antibodies; (3) Bio-Rad PlateLIA
(B; Sanofi Diagnostica Pasteur, Marnes La
Coquette, France), which detects serum IgM and
IgG antibodies with a solubilised ultrasonate of an
M. pneumoniae culture containing a high propor-
tion of membrane proteins; and (4) NOVITEC
Mycoplasma (N; HiSS Diagnostics, Freiburg, Ger-
many), which detects M. pneumoniae IgM and IgG
antibodies with a lipid antigen extract of
M. pneumoniae prepared by a proprietary purifi-
cation method. All tests were performed accord-
ing to the manufacturers’ instructions; no
duplicates were tested, and no additional meth-
ods, such as Western blot analysis, were used to
verify either false-positive or false-negative
results. Table 1 shows the cut-off values used
for the interpretation of the respective tests.
Positives, low positives and ⁄ or borderline results
were considered for determination of relative
specificities.
The detailed results of the present study are
listed in Table 2. Of the four IgM tests, the L and S
tests yielded the highest number of positive and
low-positive results in all groups, while the N and
B tests yielded the lowest figures. Of the two IgA
tests, the L test yielded more clear positive results
than the S test in all groups of sera. Four IgG tests
were available, but the N test was not assessed in
the present study, as diagnosis of M. pneumoniae
infection with this kit is based on paired
(acute ⁄ convalescent) sera. Of the remaining three
tests, IgG prevalence was highest with the L test,
followed by the S and B tests, for all groups of
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sera (Table 2). Thus, in summary, for clear pos-
itives, the IgM prevalence was L > S > N = B, the
IgA prevalence was L > S (B and N not available),
and the IgG prevalence was L > S > B (N not
done), and when low-positive or borderline
results were included, the IgM prevalence was
S > L > N > B, the IgA prevalence was L > S, and
the IgG prevalence was L > S > B.
The blood donors were asymptomatic and
were not expected to have IgM antibodies to
Table 1. Mycoplasma pneumoniae serology interpretation according to the manufacturers’ recommendations
Manufacturer IgG IgM IgA
Diagnosis ⁄
Interpretation
ThermoLabsystems < 30 – – Negative
ThermoLabsystems 30–45 – – Equivocal
ThermoLabsystems > 45 – – Positive
ThermoLabsystems – S ⁄CO < 0.5 – Negative
ThermoLabsystems – 0.5 £ S ⁄CO £ 1.1 – Equivocal
ThermoLabsystems – S ⁄CO > 1.1 – Positive
ThermoLabsystems – – < 8 Negative
ThermoLabsystems – – 8–12 Equivocal
ThermoLabsystems – – > 12 Positive
Savyon < 10 BU ⁄mL – – Negative, no
infection
Savyon ‡ 10 BU ⁄mL-< 50 BU ⁄mL – – Positive, current or
past infection
Savyon ‡ 50 BU ⁄mL – – Positive, current or
past, second
sample
needed after 2–4-
weeks
Savyon – < 10 BU ⁄mL – Negative, no
infection
Savyon – ‡ 10 BU ⁄mL-
< 20 BU ⁄mL
– Borderline, second sample
after 14–21 days
Savyon – ‡ 20 BU ⁄mL – Current infection
Savyon – – < 10 BU ⁄mL Negative
Savyon – – 10 BU ⁄mL to
< 50 BU ⁄mL
Positive, current
infection
Savyon – – 50 BU ⁄mL High positive,
current infection
Bio-Rada < 10 U ⁄mL – – Non-significant rate
Bio-Rad 10–20 U ⁄mL – – Low antibody rate
Bio-Rad 20–40 U ⁄mL – – Moderate antibody
rate
Bio-Rad > 40 U ⁄mL – – High antibody rate,
current or recent infection
Bio-Rad < 40 U ⁄mL – – Only if paired
sample is
tested 8–15 days
later
simultaneously
Bio-Rad – ODs < OD CO · 0.80 – No recent infection
Bio-Rad – OD CO · 0.80 £ ODs < OD CO Doubtful level,
results to be confirmed
10–20 days later
Bio-Rad – OD CO £ ODs – Quantitative examination
of IgG antibodies
needed,
results to be
confirmed
10–20 days later
(IgG ⁄ IgM)
Noviteca Acute ⁄ convalescentb – – –
Novitec £ 200 ⁄> 300 – – Current or recent
infection
Novitec £ 200 ⁄ £ 320 – – No significant
antibody change
Novitec > 320 ⁄ £ 200 – – Recent past
infection
Novitec – < 770 U ⁄mL – Negative
Novitec – 770–950 U ⁄mL – Low positive,
second
sample needed
2 weeks later
Novitec – > 950 – Highly significant
titre
aBio-Rad and Novitec do not provide an IgA EIA.
bNovitec’s IgG interpretation is made only on the basis of paired sera (acute and convalescent).
BU, binding unit; CO, cut-off; OD, optical density.
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M. pneumoniae. Thus, any positive ⁄ low-positive or
borderline results demonstrated by the kits tested
might be considered to be false-positives caused
by possible cross-reactivity of antibodies with the
different M. pneumoniae antigens used in the tests,
or artefacts caused by the test cut-off values. The
lowest numbers of positive results were obtained
with the N, B and S IgM EIA tests, indicating that
the antigens used for coating the microtitre plates
may be more specific for M. pneumoniae. The N and
B tests yielded the lowest numbers if borderline
and low-positive results were included. The L test
apparently uses antigens with greater cross-react-
ive potential, resulting in up to four-fold higher
numbers of positive results. The L and S tests use
P1 antigen, while the N test uses a chloroform–
methanol-extracted lipid antigen, and the B test
uses a solubilised ultrasonate of M. pneumoniae.
The differences in the extraction method and the
choice of antigen may explain minor differences in
test performance, but the cut-off values seem to be
more critical. Thus, based on the manufacturers’
recommendations, M. pneumoniae infections would
have been overdiagnosed, based on the IgM
results, in all groups tested with the P1 antigen.
Since M. pneumoniae IgA has been suggested as
an indicator of ongoing or recent infections [9–12],
it is unlikely that up to 68.5% of blood donors, or
up to 100% (with the L test groups C–F and H) of
apparently healthy populations, are seropositive.
Thus, a positive IgA result for M. pneumoniae
does not support the serodiagnosis of a current
infection.
The IgG antibody prevalences indicated by the
L, S and B kits among blood donors differed
widely, and it was difficult to reach any conclu-
sions.
In summary, each of the IgM tests evaluated
showed possible cross-reactivities, but the res-
pective cut-off definitions were the strongest
influence on test performance. The relative spe-
cificities for the IgM tests were 83% (S), 84% (L),
94.4% (N), and 96.2% (B). The relative specifici-
ties for the IgG tests were 51.3% (L), 57.5% (S)
and 62.2% (B), while those for the IgA tests were
57.7% (L) and 77.8% (S). If cut-offs and antigens
determine EIA test performance, then the rank
order of the tests was B > N > S > L.
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Table 2. Overall results for Mycoplasma pneumoniae IgG, IgA and IgM detection by enzyme immunoassays from four
different manufacturers
Seraa n
ThermoLabsystems
IgG
ThermoLabsystems
IgA
ThermoLabsystems
IgM
Savyon
IgG
Savyon
IgA
Savyon
IgM
Novitec
IgGb
Novitec
IgM
Bio-Rad
IgG
Bio-Rad
IgM
A 504 459 +
29 bl
214 +
131 bl
24 +
51 bl
49 +
323 low
20 +
95 low
4 +
77 low
–
–
7 +
12 low
31 +
307 low
10 +
4 ±
B 20 17 +
1 bl
17 +
3 bl
3 +
4 bl
7 +
8 low
5 +
11 low
2 +
11 low
– 4 +
1 low
2 + 3 +
C 15 13 + 7 +
8 bl
3 +
3 bl
3 +
8 low
1 +
10 low
6 low – 1 + 1 +
5 low
0
D 17 13 +
1 bl
8 +
9 bl
2 +
4 bl
0 +
12 low
2 +
3 low
1 +
5 low
– 2 +
1 low
0 +
7 low
1 +
E 5 5 + 3 +
2 bl
3 bl 5 low 2 low 3 low – 0 + 0 +
3 low
1 +
F 17 11 +
3 bl
14 +
3 bl
4 +
4 bl
2 +
9 low
4 +
7 low
2 +
5 low
– 2 + 1 +
5 low
2 +
G 17 15 + 9 +
7 bl
5 +
5 bl
1 +
12 low
2 +
5 low
2 +
5 low
– 3 +
2 low
1 +
3 low
2 +
1 ±
H 11 9 + 6 +
5 bl
1 bl 2 +
6 low
3 +
3 low
1 low – 1 low 1 +
1 low
0
Total 606 606 606 606 606 606 606 – 606 606 606
Positive 542 278 41 64 37 11 – 19 37 19
bl ⁄ low 34 166 75 383 136 113 – 17 331 5
Positive + low ⁄ bl 576 444 116 447 173 124 – 36 368 24
Negative 30 162 490 159 433 482 – 570 238 582
Relative
specificity (%)
51.3 57.7 84 57.5 77.8 83 – 94.4 62.2 96.2
aGroups: A, blood donors; B, acute EBV-associated infectious mononucleosis; C, adenovirus respiratory infection; D, influenza A; E, influenza B; F, Bordetella pertussis;
G, genital mycoplasma; H, systemic pneumococcus infection.
bData not given, as manufacturer allows interpretation exclusively with paired sera.
Relative specificity: true negatives ⁄ true negatives + false-positives · 100; groups A–H are presumptively true negatives.
bl, borderline.
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ABSTRACT
The interaction between sulbactam and imipenem
was evaluated with four clinical isolates of Acine-
tobacter baumannii, including two isolates resistant
to imipenem, one of which produced IMP-1
metallo-b-lactamase. Two isolates (one of which
was imipenem-resistant) were sulbactam-resist-
ant by undefined mechanisms. MICs were deter-
mined by standard broth microdilution methods.
Time-kill assays with imipenem and sulbactam,
alone or in combination at 0.5 · MIC and
1 · MIC, showed a synergic effect in all four
isolates of A. baumannii after incubation for 0, 4,
8 and > 24 h at 35C.
Keywords Acinetobacter baumannii, imipenem, sulbac-
tam, synergy
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Acinetobacter baumannii has emerged worldwide
as an important nosocomial pathogen that is
difficult to treat because of its multiple antibiotic
resistance [1]. Most nosocomial isolates of
A. baumannii are now resistant to a wide variety
of antibiotics, with carbapenems being the main
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